Selected article for: "BCG vaccine and clinical trial"

Author: Martha K Berg; Qinggang Yu; Cristina E Salvador; Irene Melani; Shinobu Kitayama
Title: Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19
  • Document date: 2020_4_7
  • ID: 44zlnswd_2
    Snippet: The BCG vaccine is used primarily against tuberculosis (4) . One review has found that BCG vaccination reduces the risk of tuberculosis by 50% (5) . A follow-up of an earlier BCG clinical trial performed on native Americans show that BCG protects people from both tuberculosis and lung cancer for up to several decades, throughout each person's life (2, 3) . A more recent meta-analysis of a broader range of observational studies and clinical trials.....
    Document: The BCG vaccine is used primarily against tuberculosis (4) . One review has found that BCG vaccination reduces the risk of tuberculosis by 50% (5) . A follow-up of an earlier BCG clinical trial performed on native Americans show that BCG protects people from both tuberculosis and lung cancer for up to several decades, throughout each person's life (2, 3) . A more recent meta-analysis of a broader range of observational studies and clinical trials (1) suggests that the effectiveness of BCG could extend to all-cause mortality. Several controlled trials provide consistent results, showing that the reduced mortality is attributable to protection against respiratory infections, as well as neonatal sepsis (6) (7) (8) . Altogether, the available evidence suggests that BCG has beneficial effects on immunity against a range of lung-related infections that go beyond tuberculosis, which makes it a promising candidate for defending against COVID-19. As for mechanisms, recent experimental work (9) finds that BCG vaccination causes genome-wide epigenetic reprogramming of human monocytes, which in turn predicts protection against experimental viral infection.

    Search related documents:
    Co phrase search for related documents